The global lysosomal alpha glucosidase market is anticipated to grow at a significant CAGR 3.5% during the forecast period (2022-2028). Lysosomal alpha glucosidase is termed as a recombinant enzyme used to treat lysosomal storage disorder known as Pompe disease (which is also known by the name acid maltase deficiency or glycogen storage disease type II). Pompe disease is perceived as an inherited fatal muscular myopathy disorder caused due to the glycogen build-up in the body cells such as in cardiac, smooth, and skeletal muscle cells. The disease is further characterized by the absence and in some cases, deficiency of the lysosomal enzyme alpha-glucosidase. The market growth is majorly driven by the growing research coupled with the increasing clinical trials that ensures a robust product pipeline for the future years.

Key players such as Sanofi have already initiated the clinical trials which spurred the market growth. For instance, in 2016, in order to treat Pompe disease, Genzyme, a unit of Sanofi, started phase III clinical trial for NeoGAA, a second generation alglucosidase alfa enzyme-based enzyme replacement therapy. Further, in 2017, Valerion Therapeutic, a clinical-stage biotechnology company specialized in the development of therapies for orphan genetic diseases, initiated phase I/II clinical trials for its candidate drug, VAL-1221 in patients with late-onset of Pompe disease. VAL-1221 combines company’s proprietary antibody-mediated delivery technology with recombinant human acid alpha-glucosidase, offering improved glycogen clearance and better patient outcomes. In February 2018, a biotechnology company named Audentes Therapeutics, Inc. conducted phase I/II clinical trial for AT982 for commercializing and developing gene therapy products to treat Pompe disease.

Market Coverage

• The market number available for – 2021-2028

• Base year- 2021

• Forecast period- 2022-2028

• Segment Covered- 

o By Product

o By Distribution Channel

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Amicus Therapeutics Inc., and Sanofi SA, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Lysosomal Alpha Glucosidase Market Report by Segment

By Product

• Myozyme

• Lumizyme

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Global Lysosomal Alpha Glucosidase Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa